$86.940
-2.226 (-2.56%)At close
LB News
LB Events
LB Pharmaceuticals Secures $150 Million Financing to Advance LB-102 Development
"We are taking meaningful steps to maximize the full potential of LB-102, leveraging clinically validated biology with purposeful innovation as the foundation for an expanded pipeline," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. "We recently announced a private placement of $150 million with participation from new and existing investors to expand the development of LB-102 into new indications where unmet needs align with the emerging clinical profile of LB-102. We are looking forward to our first pivotal trial readout and recently announced that, based on enrollment in our pivotal NOVA-2 trial in schizophrenia being more rapid than expected, we now project topline data readout in the first half of 2027, ahead of our prior guidance, and plan to schedule a pre-NDA meeting with the FDA soon thereafter in the second half of 2027. We are well positioned to advance multiple clinical programs and continue to expect topline data from our Phase 2 trial of LB-102 in bipolar depression in the first quarter of 2028 as well as data from our Phase 2 trial of LB-102 in adjunctive MDD in the first half of 2029."
Company Reaffirms FY 2026 EBITDA Outlook of $210M-$230M
The Company reaffirms its outlook for fiscal year 2026, with Adjusted EBITDA expected to be between $210M-$230M
LandBridge Forms Special Committee to Evaluate Company Structure Conversion
LandBridge Company announced that its board of directors has formed a special committee of independent directors to evaluate a potential conversion from a Delaware limited liability company to a Texas corporation. A primary driver of this evaluation is index eligibility. LandBridge anticipates such inclusion would broaden its eligible investor base, improve trading liquidity, and increase market visibility, each of which would enhance the Company's ability to pursue growth on favorable terms and support long-term shareholder value. The special committee will evaluate the potential benefits and risks of such a conversion, including the impact on LandBridge's governance structure and tax treatment
Company Raises FY2026 EBITDA Outlook to $210M-$230M
The company said, "The Company increases its outlook for fiscal year 2026, with Adjusted EBITDA expected to be between $210 million and $230 million. This updated guidance reflects increased visibility and conviction in our commercial pipeline for the remainder of 2026, combined with a more supportive macroeconomic environment."
Company Reports Q1 Revenue of $51.0M, Below Consensus
Reports Q1 revenue $51.0M, consensus $59.52M. The company said, "We're pleased to have delivered first quarter results that reflect strong year-over-year growth and solid commercial momentum heading into the second quarter, with second-half growth drivers on track. Since the beginning of the year, we have been able to close several bolt-on acquisitions that further enhance the scale and contiguity of our acreage position, and our recent agreement with PowerBridge for the Alpha Digital Campus further demonstrates the strength of commercial demand across our acreage. Our active land management strategy continues to attract high-value commercial opportunities, driving durable and high-margin growth, and providing us with the confidence to raise our full year Adjusted EBITDA guidance range."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.